Feng Guowen, Zhou Xiaodan, Chen Jia, Li Dan, Chen Li
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.
Front Oncol. 2023 Jan 11;12:1012093. doi: 10.3389/fonc.2022.1012093. eCollection 2022.
With the widespread application of platinum drugs in antitumor therapy, the incidence of platinum drug adverse events (ADEs) is always severe. This study aimed to explore the adverse event signals of Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, and to provide a reference for rational individualized clinical drug use.
The adverse event report data of the three platinum drugs from the first quarter of 2017 to the fourth quarter of 2021 were extracted from the FAERS database, and the data mining and risk factors for the relevant reports were carried out using the reporting odds ratio (ROR) method the proportional reporting ratio (PRR)and the comprehensive criteria (MHRA) method.
A total of 1853 effective adverse event signals were obtained for the three platinum agents, including 558 effective signals for Cisplatin, 896 effective signals for Carboplatin, and 399 effective signals for Oxaliplatin. The signals involve 23 effective different system organs (SOCs). The adverse events of Cisplatin are mainly fixed on blood and lymphatic system diseases, gastrointestinal diseases, systemic diseases and various reactions at the administration site. The adverse events of Carboplatin are mainly focused on blood and lymphatic system diseases, respiratory system, thoracic and mediastinal diseases, while the adverse events of Oxaliplatin are mainly concentrated in respiratory system, thoracic and mediastinal diseases, various nervous system diseases, and gastrointestinal system diseases.
It was found that the main systems involved in common adverse events of platinum drugs are different, and the correlation strength of platinum drugs with the certain adverse events of each system is different.
随着铂类药物在抗肿瘤治疗中的广泛应用，铂类药物不良事件（ADEs）的发生率一直很高。本研究旨在探索顺铂、卡铂和奥沙利铂这三种广泛使用的含铂药物的不良事件信号，为临床合理个体化用药提供参考。
从FAERS数据库中提取2017年第一季度至2021年第四季度这三种铂类药物的不良事件报告数据，并采用报告比值比（ROR）法、比例报告比（PRR）法和综合标准（MHRA）法对相关报告进行数据挖掘和风险因素分析。
三种铂类药物共获得1853个有效不良事件信号，其中顺铂有效信号558个，卡铂有效信号896个，奥沙利铂有效信号399个。这些信号涉及23个不同的有效系统器官（SOCs）。顺铂的不良事件主要集中在血液和淋巴系统疾病、胃肠道疾病、全身性疾病以及给药部位的各种反应。卡铂的不良事件主要集中在血液和淋巴系统疾病、呼吸系统、胸及纵隔疾病，而奥沙利铂的不良事件主要集中在呼吸系统、胸及纵隔疾病、各种神经系统疾病和胃肠道系统疾病。
发现铂类药物常见不良事件所涉及的主要系统不同，且铂类药物与各系统特定不良事件的关联强度也不同。
